Enjoy complimentary customisation on priority with our Enterprise License!
Dermatophytic onychomycosis is a fungal infection that is caused by yeast, dermatophytes, and molds, and affects the nail plate, nail bed, and, in some cases, the skin surrounding the nail plate. Factors such as the rising prevalence of dermatophytic onychomycosis, heavy investments to develop therapies, and frequent product innovations will aid in the steady growth of the dermatophytic onychomycosis market size during the forecast period. Moreover, the large-scale availability of promising products in the pipeline and the recent rise in diabetic population will result in this market’s steady CAGR of more than 7% by 2020.
An important factor that will impel the prospects for growth in this market is the augmented focus on combination therapies. Recently, it has been observed that a combination of topical and systemic treatment increases the cure rate when compared to individual therapies. Since combination therapies have improved clinical efficiency and are more cost-effective than terbinafine, they are increasingly being preferred over individual terbinafine-based therapies as they have a higher cure rate.
In this market research, analysts have estimated the oral route of drug administration to be more effective when compared to the topical route of drug administration. Medications administered orally ensure a systemic effect as they undergo the first-pass metabolism and are mostly absorbed by the small intestine. Oral drugs include both approved (Lamisil, Sporanox, and Fulvicin) and off-label (Diflucan) drugs.
In 2015, the Americas dominated this market and is envisaged to retain its dominating market position by the end of 2020 owing to the presence of a well-developed healthcare system. The market in this region is anticipated to reach close to USD 2 billion by 2020.
The global dermatophytic onychomycosis market is intensely competitive owing to the presence of numerous small and large vendors that operate at a local or global scale. To survive and succeed in this market, the vendors enter into strategic alliances with smaller players to manufacture and market new drugs.
Key vendors in this market are
Other prominent vendors in this market are Abeona Therapeutics, Allergan, Elorac, GlaxoSmithKline, Hexima, Hisamitsu Pharmaceutical, Mayne Pharma, MediQuest Therapeutics, Meiji Seika Pharma , Merz Pharma, Moberg Pharma, NanoBio, NovaBiotics, Nuvo Research, Pfizer, Polichem, Promius Pharma, Sanofi, Seren Pharmaceuticals, Taro Pharmaceutical, Topica Pharmaceuticals, and Viamet Pharmaceuticals.
Technavio also offers customization on reports based on specific client requirement.
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Overview: Dermatophytic onychomycosis
PART 06: Pipeline analysis
PART 07: Market landscape
PART 08: Market segmentation by route of administration
PART 09: Geographical segmentation
PART 10: Market drivers
PART 11: Impact of drivers
PART 12: Market challenges
PART 13: Impact of drivers and challenges
PART 14: Market trends
PART 15: Vendor landscape
PART 16: Appendix
PART 17: Explore Technavio
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.